Home / Transcripts / RxSight, Inc. (RXST) · February 25, 2026

RxSight, Inc. (RXST) Earnings Call Transcript

February 25, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 42 min

Earnings Call Speaker Segments

Oliver Murovec executive
#1

Thanks, operator. Joining us on the line today are RxSight's President and Chief Executive Officer, Dr. Ron Kurtz, along with our Chief Financial Officer, Mark Wilterding. Earlier today, RxSight issued its financial results covering the 3 months that ended December 31st, 2025. You can find a copy of that press release posted on the company's website. Before we get started, I want to let everyone know that what we say and how we answer questions on today's call represents management's views only as of today, February 25th, 2026, and it will include forward-looking and opinion statements — things like predictions, estimates, plans, expectations, and other information. Actual results could differ materially from what's expressed or implied because of certain risks and uncertainties; those risks and uncertainties get a fuller description in the press release we issued today as well as in our filings with the Securities and Exchange Commission, or SEC. Our SEC filings are available on our website or on the SEC's website. We caution investors against placing undue reliance on forward-looking statements, and we disclaim any obligation to update or revise those forward-looking statements except as may be required by law; in addition, we will discuss certain non-GAAP financial measures. Disclosures about non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please be aware that an audio replay of this conference call will be available on our investor relations website. With that, I'll hand the call over to Ron. Ron?

Ron Kurtz executive
#2

Good afternoon, everyone, and thanks for being with us today. First, I want to welcome Mark to his very first RxSight earnings call, and I'd also like to ask him to get us started by walking through our financial results for the fourth quarter and the full year 2025, covering the main factors behind that performance as well as the trends we're seeing throughout the business. Once he's finished, I'll talk about what our team accomplished during the fourth quarter and lay out the actions we're taking to set RxSight up for 2026 and the years ahead. So with that, let me hand things over to Mark.

Mark Wilterding executive
#3

Thanks, Ron, and good afternoon to all of you. As we said in our January pre-announcement, RxSight's fourth quarter 2025 sales came in at $32.6 million, a 19% decline versus the prior-year period, which reflects lower LDD sales. You'll remember that the year-ago quarter set records for LDD placements, with 83 units sold around the world, which brought in $11 million of sales. During the fourth quarter of 2025, we moved 25 LDD units worldwide and brought in $3 million of LDD revenue. Even with that year-over-year drop in the fourth quarter, we closed out 2025 with an LDD install base of 1,134 units, which is 17% above the 971 units in place at the close of 2024. Now on to LALs. In the fourth quarter, our LAL sales totaled 28,611, which is 2% below the year-ago period but 10% higher on a sequential basis. Procedure volumes produced $28.2 million in LAL sales during the fourth quarter of 2025, matching Q4 2024. LAL revenue made up an all-time high of 86% of total company sales in the fourth quarter, rising from 71% in the year-ago period. This richer LAL revenue mix helped push gross margin to 77.5% in the fourth quarter of 2025, versus 71.6% in the year-ago period. SG&A expenses for the fourth quarter of 2025 totaled $27.7 million, a 2% decrease from the prior-year period, mainly from lower personnel-related expenses, partly offset by ongoing investments in LAL commercial initiatives. Research and development expenses in the fourth quarter came to $8.9 million, down 3% year-over-year and 2% sequentially, driven by lower personnel-related expenses, partly offset by continued investment in moving our research and development pipeline forward. We posted a net loss of $9.2 million for the fourth quarter of 2025, or $0.22 per basic and diluted share, on 41.2 million weighted average shares outstanding. Stock-based compensation came to $7.8 million, which left us with an adjusted net loss of $1.3 million, or $0.03 per share. I'll now give a quick recap of full year 2025 results. Full year sales reached $134.5 million, up 4% year-over-year, driven by a 48% drop in LDD revenue that was partly offset by a 12% rise in LAL sales. Gross profit margin for 2025 was 76.6%, versus 70.7% in 2024, mainly because of a higher LAL revenue mix. Total operating expenses reached $151.2 million in 2025, an 11% increase over 2024. That year-over-year expense growth came primarily from higher personnel costs and continued investments in research and development, along with commercial activities supporting our long-term strategy. For the full year 2025, our net loss was $38.9 million, or $0.95 per share, compared with a net loss of $27.5 million, or $0.71 per share, in 2024. If we exclude $31.6 million in stock-based compensation expense, our adjusted net loss for 2025 was $7.3 million, or $0.18 per basic and diluted share. Shifting to the balance sheet: we finished the year with no debt and roughly $228 million in cash equivalents, and short-term investments. Now let's turn to 2026 guidance. For the entire year, we're guiding revenue to between $120 million and $135 million, which works out to roughly a 5% decline compared with the prior year at the midpoint, mostly because LDD sales came in lower than they did a year ago. When it comes to 2026, we expect the first quarter to show the weakest sales, which reflects the usual seasonal pattern along with tougher year-ago comparisons. Sales in the third quarter of 2026 will likewise feel seasonal effects, though we do expect total company sales growth to pick back up during the back half of the year, since comparisons get easier and our commercial efforts start to take hold. For 2026, we're expecting only a fairly modest amount of revenue from outside the U.S., mainly through early capital placements, as we move deliberately when it comes to growing internationally. Right now the team is working on developing ties with key opinion leaders and gathering clinical data specific to each country, which should set the company up for more substantial international sales in 2027 and later. Our gross margin guidance for the full year 2026 sits at 70%-72%. That's below where we were in 2025, yet it lines up with the company's gross profit margin profile back in 2024. We've taken a conservative stance in our 2026 gross margin guidance to account for higher-cost inventory selling through, which stems from production levels in 2025 that came in below what we'd originally planned. Even so, we look for manufacturing absorption headwinds to lessen as time goes on. For 2026, we expect operating expenses to land somewhere between $150 million and $160 million, which represents a 1% decline at the bottom end of that range and a 6% rise at the top end versus the previous year, and it mirrors the continued investment we're making in international expansion as well as our U.S. sales and marketing push. We expect R&D spending to come in roughly flat against 2025 levels. Within our costs, largely in operating expenses, there's non-cash stock-based compensation expense of $30 million-$32 million. With that, I'll hand things back over to Ron.

Ron Kurtz executive
#4

Thanks, Mark. While our results for the entire year fell short of what we had originally projected, 2025 represented twelve months of significant advancement for RxSight, and I'd like to express gratitude to our 500 team members and thousands of clients, since collectively we moved forward the worldwide distribution of our transformative LAL technology. Roughly 5 years after our IPO gave us the ability to introduce adjustability on a broad scale throughout North America, our clinical results continue to be the finest available, as physicians and patients stay deeply involved with both this technology and adjustable procedures, which account for roughly 10% of the U.S. premium market in terms of volume and around 15% when measured by revenue, confirming that adjustability has moved beyond being merely an idea and is now a proven category possessing genuine commercial and clinical support. During 2025, after several years of swift growth that led to roughly 25% of U.S. cataract surgeons receiving training in this emerging approach, we made a series of strategic choices aimed at reinforcing clinical and practice capabilities throughout our customer base, refining how we handle training, education, and assistance for both new and established practices and physicians. Even though we remain at an early stage in obtaining outside confirmation of this process, we've been heartened by recent patterns suggesting these initiatives are starting to gain traction. To be more specific, and as Mark described, procedure volumes rose on a sequential basis during the fourth quarter, mostly because of LAL usage among our customers. Given that we have more than 1,100 LDDs deployed and an even greater count of practitioners, additional work lies ahead, which underscores the considerable chance we have to further capitalize on our installed base to generate same-store sales and improve patient outcomes. Simultaneously, we've adopted a more rigorous stance regarding capital placements, intending to keep delivering sustainable execution via outstanding clinical results, robust customer adoption, and streamlined practice workflows that underpin long-term achievement. Looking forward, our commercial priorities are well defined. Boost utilization among our current installed base by means of focused practice engagement and fresh education programs, and broaden access to our technology in a careful manner via disciplined LDD placement and developing access models. We think that carrying out these things consistently will bring the business back to sustainable growth, with adjustability holding a distinctive place in the premium eyewear market to tackle the unmet requirements of physicians and patients alike, and the clinical rationale behind this is backed by both formal clinical trials and real-world evidence. On that note, we're happy to share that earlier this month, findings from our post-approval study were accepted for publication in the Journal of Cataract & Refractive Surgery. The paper by Dr. Jack Holladay stated that 93% of LALs attained both spherical equivalent and residual cylinder within a half diopters of target, showing statistically superior refractive accuracy relative to historical studies of contemporary toric IOLs. Equally significant, nearly identical outcomes were found in a data registry of more than 20,000 LAL eyes presented by Dr. John Doane at yesterday's meeting of the American-European Congress of Ophthalmic Surgery. We're adding strong big data to the expanding evidence base that backs the LAL platform and the capacity of postoperative adjustability to deliver unmatched refractive precision across a wide patient population, cutting down on outliers and allowing refractive customization — which together lift patient satisfaction and expand premium procedures. Since conventional cataract reimbursements keep facing downward pressure, we think the LAL is positioned well to produce the outstanding outcomes patients demand, plus the improved profitability that matters more and more for keeping ophthalmic practices viable. RxSight stays dedicated to pushing adjustability toward still higher performance, as shown by roughly 20 FDA approvals directly supporting product development across the last five years, with multiple new submissions planned during the coming 18 months. Through these efforts, LAL technology keeps getting simpler for a broader set of customers to adopt by boosting the overall value proposition for physicians and patients alike. We think this record-breaking pace of innovation offers yet another chance to connect with customers as we deepen familiarity with and use of already launched lens features such as ActivShield, LAL+, and expanded IOL powers, along with recently introduced LDD capabilities and our updated LDD and insertion device platforms — with still more innovation on the way. Abroad, we're constructing a lasting foundation for long-term success, concentrating over the next year on working with local clinicians to cultivate key opinion leaders throughout Europe, Asia, and now Australia, who can produce their own early in-country outcomes and turn into advocates for adjustability in these major markets, where most global premium IOL procedures take place. As time goes on, we think rising myopia prevalence and earlier cataract surgery in international markets amount to meaningful long-term tailwinds for the LAL, since optimizing binocular vision and refractive accuracy grow increasingly important for patients pursuing spectacle independence and high-quality visual performance. We're also putting the lessons from North America to use so our teams and practices are properly prepared to succeed when they bring this paradigm to their patients; in summary, we're encouraged by the progress seen in the latter part of the year, with early indications of improvement and an organization better aligned to produce superior clinical outcomes. At the same time, we're realistic and taking a prudent approach toward the durable opportunity RxSight's adjustable platform has created. There's definitely more work ahead, and our focus is on delivering consistent performance over time; with an improved commercial structure, a large installed base, continued innovation, early infrastructure in key international markets, and a strong balance sheet, we believe the foundation is in place to execute deliberately and build momentum; we're confident the LAL platform will keep helping more patients globally, positioning the company to drive strong growth in the years to come, as stakeholders increasingly recognize the significant benefits of RxSight's differentiated technology. With that, I'll ask the operator to open up the call for questions.

Executive executive
#5

Hello, Alan here, filling in for Robbie. I have a brief question regarding the 2026 guidance. I'm interested in what you've observed up to now concerning the fundamental condition of the market, for both LALs and LDDs. As you're aware, you closed out the year with a quarter that came in somewhat ahead of projections on the LAL side. I'd like to know how we ought to view that trend as it develops across 2026, and what assumptions are baked into the guidance.

Ron Kurtz executive
#6

Well, um, I appreciate that question, Alan. I believe, you know, we did notice a slight increase in Q4. And, you know, I think we're definitely hoping that it keeps going through 2026. The guidance, you know, clearly factors that in as a possibility, but perhaps I'll let Mark add more on that.

Mark Wilterding executive
#7

Correct, and the guidance certainly reflects that. Quarterly guidance isn't something we provide, as you're aware, though our full-year outlook does incorporate the trends we've seen so far this year. Keep in mind, looking back 12 months, Q1 2025 stood as our strongest LDD volume quarter and our second-highest LAL unit volume quarter. Company-wide sales, I believe, rose roughly 30% versus the prior year. That's a tough comparison, and we wanted that factored in alongside everything else when setting our guidance.

Executive executive
#8

Let me just ask one more thing about gross margin, following up quickly. In the past, if I recall correctly, you mentioned that from a gross margin standpoint, high 70s remained achievable looking ahead. Obviously, with manufacturing variances in 2026, there's some near-term pressure you're experiencing. Looking at 2027 and past that, is there anything that would prevent that from climbing back to the high 70s? Thanks for taking the questions.

Mark Wilterding executive
#9

Sure, we definitely keep a close eye on that, as you'd expect. Over the longer haul, our view on it hasn't changed. We've demonstrated it can be done. Those kinds of margin levels were reached by us in the prior year. In the end, I'd say it hinges largely on whatever assumptions you hold regarding how the business's mix profile will look. Historically speaking, much of the margin improvement stemmed from a rising share of LALs within the mix. Since those carry a richer margin profile, that's clearly something to factor in. Another point worth mentioning on the margin side is that international remains at an early stage, so as it continues to scale up, that too could play a role in shaping the company's gross margin profile over the long term.

Larry Biegelsen analyst
#10

Afternoon. Appreciate you fielding this, Mark. And congratulations on stepping into the new position. Because this marks your initial one as CFO, I'm curious to hear about your approach, your philosophy, and in particular, what magnitude of a decline do you anticipate for LDD placements? Would somewhere between 50% and 60% compared with a year ago be a reasonable band? And what sort of expansion do you figure for LAL volume? Is growth in the mid-single digits a sensible expectation — does mid-single digit growth feel like a solid target? I also had a second question.

Mark Wilterding executive
#11

Of course. Thank you, Larry. To begin with the philosophy behind guidance, as I step into this position, my emphasis is squarely on establishing targets that can be hit. That's built from a bottoms-up projection. When it comes to 2026, we're looking at what has played out so far this year in terms of trends. Like Ron said, we're observing initial indications of things getting better, yet we prefer to stay grounded and adopt a cautious stance, and I want the guidance to capture that. More effort remains ahead, though what we're concentrated on is producing steady results across time. You raised a point regarding LDD assumptions. What we're assuming is a modest pickup relative to the roughly 25 units per quarter that marked the 2025 exit rate, and that figure ought to climb as the year progresses, helped by added contributions from certain OUS units too. For Q1, my expectation is that units will be at their lowest where LDD sales are concerned. On the subject of LAL unit growth, I'd say it's reasonable to expect, across the entire year, something within that low single-digit range for unit growth in LALs.

Larry Biegelsen analyst
#12

That's really useful, Mark. Regarding gross margin, could you give us a bit more detail there? Our understanding has always been that LALs carry a better gross margin than LDDs. How long will those manufacturing variances you mentioned stick around? If I'm doing the math right, it also appears pricing on LDDs came down in Q4. Please give us your thoughts on how that plays out going forward too. Thank you.

Mark Wilterding executive
#13

I'd say, when it comes to how gross margin will trend across the year, we expect we'll still be burning off some of that cheaper inventory during this year's first quarter; because of that, Q1 gross margin could very well land above that range. That said, as the year progresses, we do expect that pricier inventory to flow through the system, starting in the second quarter. Given that, we believe 70%-72% gross margin is, as I mentioned, the sensible target for the entire year. The higher LDD unit sales we anticipate in the back half; that ties into, I'd say, the second part of what you asked about mix; those are also apt to add some further strain on that margin, the gross margin profile.

David Saxon analyst
#14

Great. Yeah, good afternoon, and thank you for taking my questions. I'd like to ask a follow-up regarding the gross margin. In the second quarter, inventory with higher costs begins to move through. How much time is required for that inventory to, sort of, clear out, and for us to observe, you know, the actual underlying, you know, unit cost, when it comes to LALs?

Mark Wilterding executive
#15

You know, that's a good question. Thank you. Like we stated, our view is that it's transient. Throughout the year, we'll make our way through it. As I noted, when answering Larry's question, it appears at first in the second quarter, after which it becomes something we'll need to deal with in the third and fourth quarters too. Past that point, we're tracking it carefully and keeping very close watch on the situation. Our belief, in the end, is that, you know, we've set ourselves up from an inventory position in line with what we expect for growth in 2026 and afterward. I think that's likewise factored in when considering that guidance.

David Saxon analyst
#16

All right, that's helpful. Thanks. My follow-up question concerns the momentum you're getting from this commercial shift. I'd like to hear about what you're observing, whether there are any wins you can point to, and what exactly is unfolding that makes you feel good about the second-half rebound you mentioned in the script. Thanks very much.

Ron Kurtz executive
#17

Yes. Thanks, David. It's exactly what you referred to. As our teams concentrate on specific practices and their particular requirements via a structured program, we're already seeing some initial wins. Our view is that this will keep going as we bring on a greater number of clinical sites.

Steve Lichtman analyst
#18

Thanks. Good evening, everyone. Ron, regarding those initiatives, I'd like to know what you've observed up to now concerning how well they're holding up. My question, I suppose, is how much time this more intensive push requires before any real shift occurs, and once your people step away, do the gains persist?

Ron Kurtz executive
#19

Steve, in my view it's too soon to say much about that. Practices, as you know, are always in flux. Doctors change, staff change, so assuming we can simply arrive, do the work once, and have everything running smoothly again probably isn't the right way to think about it; we intend to remain engaged with our customers. There are additional reasons for that, since we keep bringing more capabilities into the technology. My sense is we'll keep at it, though perhaps with reduced intensity, and that intensity will differ — it will differ — based on what each practice specifically requires. We don't expect this to be a single-pass effort.

Steve Lichtman analyst
#20

All right. Thanks for that, Ron. And then the second thing I wanted to ask about is how did you take the competitive landscape into account for 2026, and is there anything qualitative you can share about what you're observing in the market and, once again, how that's being incorporated into your thinking? Thanks.

Ron Kurtz executive
#21

So we definitely keep an eye on what's happening competitively. If you remember, 2025 was an odd set of circumstances in which all three of our largest rivals were bringing out prominent new multifocal IOLs at the same time. We're not really expecting a repeat of that; even so, we're already aware there have been announcements about new premium IOLs, especially in presbyopia correction, coming from certain big companies as well as a few of the other participants in this area. So, much like we discussed regarding 2025, these sorts of developments are typically short-lived and come in waves. They happen when promotional activity clusters around the release of something new. Eventually, what you find with the so-called new technology is that it's basically no different from what came before. And that tends to produce a natural drift back to where things started.

Anthony Petrone analyst
#22

Hello, Anthony Petrone here, speaking on behalf of Travis. I have a question regarding the assumptions about utilization for LALs. You mentioned that volumes rose by a mid-single digit percentage, but perhaps my calculation is incorrect, since that would suggest utilization has declined, so could you elaborate on that? Thanks.

Mark Wilterding executive
#23

Thank you, Aidan, for asking. When it comes to growth in LAL units, an increase within the low single-digit range is, I believe, the correct way to view it, and that means utilization levels out at approximately 8 lenses per LDD each month.

Anthony Petrone analyst
#24

All right, that's helpful. Thanks. Regarding the premium segment overall, I believe your comment was that 40% of LAL patients would otherwise have gotten a non-premium lens. As we consider total market expansion, how should we frame RxSight's contribution, or the extra point of market growth? Thanks.

Ron Kurtz executive
#25

Yes, like we've mentioned before, if you review the previous five years and examine how the premium category grew, an extremely big share of that came from the LAL — precisely because of what you just described: it draws patients who are unable or unwilling to accept any trade-off in vision quality. Our view is that this will keep going, particularly as the market trends we're seeing persist, for example younger patient groups pursuing cataract surgery sooner, and as a result being less willing to tolerate decreases in contrast, vision, and other quality-of-vision metrics that the LAL does not affect. We expect those trends to carry on.

Adam Maeder analyst
#26

Hi there, good afternoon to you both, Ron and Mark — and Mark, congrats on stepping into the new position.

Mark Wilterding executive
#27

Appreciate it, Adam.

Adam Maeder analyst
#28

I've got a couple of questions. The first concerns the guidance, and the second concerns international. Regarding guidance, I was hoping you could provide a bit more detail, specifically about how the models are sequenced. When we look at FY 2026, is the correct framework that Q1 represents the low point, followed by sequential gains each quarter for the remainder of the year? I also caught the mention of recovery during the back half, plus the fact that comparisons get easier. Does that imply we should expect year-over-year growth to be positive during the second half? I have one more question after that. Thanks.

Mark Wilterding executive
#29

Yes, thank you, Adam. When it comes to sales for the company overall, my sense is that Q1 will be the seasonally softest period, which matches our normal pattern, and there will additionally be some summer-driven challenges affecting the third quarter. On the subject of year-over-year growth rates, our expectation is that they will strengthen as the year progresses, quarter by quarter, reflecting our belief that fundamentals will keep getting better and that year-over-year comparisons will become less demanding. Your description of how to think about it matches what we expect.

Adam Maeder analyst
#30

Alright, that's great. Thanks for the answer. Regarding international, it seems like the guidance includes a small amount of revenue from outside the U.S. Could you clarify which regions are driving that? Also, I'd appreciate any fresh details on when approvals might come through for Japan and China. Thanks.

Ron Kurtz executive
#31

Yeah, so as we've mentioned in the past, we've gotten clearances in the European Union, the U.K., and certain Asian nations — South Korea, Singapore, and a few others in Asia — plus Australia more recently. Obviously, the sales would probably originate from those places. We've discussed before the longer timelines involved in getting regulatory sign-off in China and Japan. Those efforts are underway, and we'll share more information on that before the year is out.

Adam Maeder analyst
#32

Appreciate it, Ron.

Danielle Antalffy analyst
#33

Hi there, good afternoon. My apologies for that. Thank you very much, everyone, for fielding the question. I just wanted to ask something to dig slightly further into the opportunity overseas. I'd love it if you might elaborate a bit — I realize it's likely still early — on the go-to-market approach you're contemplating there, particularly when it comes to placing systems, given the budget limitations in international markets and how competitive things are. Many thanks.

Ron Kurtz executive
#34

Yeah, so I'd say, you know, at a high level, the, well, as we have discussed, the market outside the U.S. is in fact roughly twice as large as the market here in the United States, and it's clustered across about 20 separate nations. It's definitely something a business of our scale can go after. We have, you know, started securing our regulatory clearances and building a presence — either via a direct team or by working with a distributor — in the places where those first approvals have come through. What we're concentrated on at this moment is building up KOLs and clinical evidence in those geographies. Because we, you know, obtained approvals without needing to run a clinical trial the way we did here in the United States, where we had what I'd call a ready-made KOL base of roughly 20 sites from the start; we have to build that same thing again. Naturally, we do intend to take advantage of everything we've learned across the last five years, and that is definitely what we plan to do.

Danielle Antalffy analyst
#35

All right, that's useful. And now a brief follow-up about the wider market. I mean, you know, since our conversations with doctors happen kind of individually, I can't be sure how typical a couple of physicians really are, yet it does appear that conditions across the broader market are getting better for the premium IOL category as a whole. I realize you folks are going through your own kind of transition right now, but I'm wondering whether you hold any view regarding the larger premium portion of the market, and — I'm not certain accelerating is the correct term — but is it re-expanding or moving yet again following what seems like a 24 that was quite suppressed from a, sorry, 25, quite suppressed when it comes to penetration? Many thanks.

Ron Kurtz executive
#36

Thanks. I, you know, I believe we've picked up from certain third parties and other participants in this market that the premium market saw a bit of acceleration near the close, during the year's second half. You know, that would line up with what we've seen. The premium market, you know, has historically tended to hold up better against macro headwinds. Even though there are a few murmurings of those, I think that, you know, we would hope that the — that such historical patterns would keep going ahead, and certainly given that the LAL kind of sits at the higher end of the premium market, that our customers would be less sensitive to those.

Tom Stephan analyst
#37

Thanks for fielding our questions, everyone. I'd like to begin with the guidance. Ron or Mark, could you walk us through what I'd describe as the main underlying drivers — or what exactly is baked in — that would land you at the upper bound of that range? It's a pretty broad range, so I'm just wondering what pushes you toward the high end?

Mark Wilterding executive
#38

Absolutely, Tom, I'll take that one first. Appreciate you asking. When we consider the upper bound, the $135 million figure, it presumes that certain internal programs Ron discussed and brought everyone up to speed on gain more momentum — that's the initial premise, I'd say. Past that, we'd factor in a quicker improvement in utilization, with that growth being particularly pronounced during the back half of the year. Assumptions around competitive trialing would be the third element. Naturally, reduced pressure from competitive trialing would work in our favor too, pushing us toward that range's ceiling. Ron, is there anything else you'd include?

Ron Kurtz executive
#39

No, I'd say that's a solid—

Tom Stephan analyst
#40

Understood.

Ron Kurtz executive
#41

—topic for us to talk through.

Tom Stephan analyst
#42

Understood, that's really useful. Ron, perhaps turning to you now, I'd like to ask about pipeline innovation. I'm just wondering whether there's anything you're able to share or offer regarding what might be coming down the road in terms of updates or progress on development. It feels like we haven't gotten much news recently. I suppose I'll just come out and ask: are there any new lenses potentially ahead from RxSight that we can anticipate? Thanks.

Ron Kurtz executive
#43

Sure, obviously, it depends on the timeframe, but we'll keep innovating on both the lens side and the LDD side, plus some of the other auxiliary devices tied to our technology. I think the finest approach to responding to that is to go over how quickly we've innovated, particularly across the past five years. Over 20 meaningful FDA approvals tied to products. That speed, I'd say, is truly unmatched within the industry. Even with the innovations we've already launched, we still have chances to keep penetrating the market with them. With more than 1,100 systems and 2,500 customers, even before adding anything further, which we do intend to do, we still have plenty of raw material to work with. Just to frame it more historically, we're roughly 5 years into this. Usually, the technologies I've been involved with have had 10 to 15-year stretches of major technological innovation. So I believe there remain numerous additional applications where adjustability will prove advantageous.

Tom Stephan analyst
#44

Okay, thanks, Ron.

Ron Kurtz executive
#45

Alright, I appreciate it, Operator, and I want to thank everyone for the attention you've shown toward RxSight. We're eager to bring you news about how things are going in the quarters ahead. Take care.

Operator operator
#46

Everyone, that brings us to the end of today's call. We appreciate your participation. You can go ahead and disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete RxSight, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to RxSight, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.